Mundipharma bags rights to Vectura’s novel respiratory therapy
Mundipharma has signed a deal with Vectura to develop and commercialise VR2076, a novel inhaled triple therapy in development for the treatment of asthma and COPD.
Read More
Tag: VR2076
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
